Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent
Source: SeekingAlpha
2025-09-03 09:19:11 ET
More on Ionis Pharmaceuticals
- Positive CORE and CORE2 Topline Results
- Ionis Pharmaceuticals, Inc. (IONS) Positive CORE And CORE2 Topline Results (Transcript)
- Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma
- Ionis gains on late-stage trial win for hypertriglyceridemia therapy
- Ionis gains FDA approval for RNA therapy donidalorsen for hereditary angioedema
Read the full article on Seeking Alpha
For further details see:
Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent
Amarin Corporation plc
NASDAQ: AMRN
AMRN Trading
-4.29% G/L:
$15.60 Last:
33,812 Volume:
$16.39 Open:
AMRN Latest News
March 07, 2026 01:35:00 am
Here's Why I Wouldn't Touch Amarin With a 10?Foot Pole Given Its Patent and Competition Risks
AMRN Stock Data
$312,618,004
18,426,477
1.2%
30
N/A
Pharmaceuticals
Healthcare
IE
Dublin 2
